Prelude Capital Management’s AstraZeneca AZN Stock Holding History

Prelude Capital Management’s Portfolio AZN Stock Details AZN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-37,500	Closed	-$4.49M	–	1735
2021 Q2	$4.49M	Buy	+37,500	New	+$4.11M	0.13%	100
2020 Q3	–	Sell	-250	Closed	-$26K	–	1819
2020 Q2	$26K	Buy	+250	New	+$25.8K	﹤0.01%	1330

Other funds holding AZN

Investor AB Stockholm, Sweden $15.1B AUM 29.02% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Legal & General Group London, United Kingdom $432B AUM 29.4% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

VAM

Vanguard Asset Management London, Ec4n 8af $117B AUM

Prelude Capital Management's AZN Position: Q1 2026 in Review

Prelude Capital Management opened a new position in AstraZeneca (AZN) in Q1 2026: 7,160 shares worth $1.39M. The stake represents 0.11% of the portfolio and ranks #229 among its holdings. This is a return to the name: Prelude Capital Management previously reported a position in AZN as recently as Q3 2022.

Prelude Capital Management first reported a position in AZN in Q2 2014 and has held it in 20 quarters since. The position peaked at $1.4M in Q2 2022. 1,379 funds tracked by Wall St. Rank hold AZN as of Q1 2026.

Prelude Capital Management held 7,160 shares of AstraZeneca worth $1.39M as of Q1 2026.
AstraZeneca was a new Prelude Capital Management position in Q1 2026.
AstraZeneca made up 0.11% of Prelude Capital Management's portfolio in Q1 2026, its #229 holding.
Prelude Capital Management first reported a position in AstraZeneca in Q2 2014 and has held it in 20 quarters since.
Prelude Capital Management's AstraZeneca position peaked at $1.4M in Q2 2022.
1,379 funds tracked by Wall St. Rank held AstraZeneca as of Q1 2026.

Based on Prelude Capital Management's 13F filing for Q1 2026, filed 15 May 2026.